Afrezza market outlook brightens on rising diabetes demand

The Business Research Company says the global Afrezza market is set for stronger growth through 2035 as diabetes cases rise, healthcare spending increases and inhaled insulin gains wider acceptance. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Afrezza is an inhaled insulin option for diabetes management, and stronger demand could widen use of needle-free treatment alternatives. - The market outlook matters for diabetes care because rising patient numbers and treatment preferences are pushing more attention toward rapid-acting, post-meal blood sugar control.

What happened: - The Business Research Company published Afrezza Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 29, 2026. - The report says the Afrezza market has grown on the back of rising diabetes prevalence, the challenges of injectable insulin, regulatory approvals for inhaled insulin products and early adoption in adult diabetes care. - The report also projects faster growth ahead as type 2 diabetes cases expand and inhalation drug delivery becomes more accepted. - The company highlighted North America as the largest regional market in 2025. - The company identified Asia-Pacific as the fastest-growing region during the forecast period. - More information is available in a free sample report and the full market report.

The details: - Afrezza is an inhalable insulin absorbed through the lungs. - The drug is designed to help people manage blood glucose levels quickly. - Afrezza is used primarily to control postprandial hyperglycemia, or blood sugar spikes after meals. - The report says higher diabetes prevalence is a major demand driver. - Rising diabetes rates are linked to obesity, sedentary lifestyles, poor diet, aging populations, urbanization, genetic factors and better diagnosis and awareness. - UK data cited in the report showed that the share of people with type 1 diabetes receiving comprehensive care at GP practices rose from 35.2% in 2022 to 43.8% in 2023. - The report says growing healthcare spending also supports adoption of Afrezza and related monitoring and device costs. - A UK Office for National Statistics report cited in the release showed total healthcare expenditure rose 5.6% nominally from 2022 to 2023, after a 0.9% rise in 2022. - The same UK data showed real-term spending on long-term health and social care increased 2.8% in 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The report points to a market shift toward convenience in diabetes treatment, with needle-free options gaining appeal as patients and clinicians look for easier alternatives to injections. - The focus on better safety data, more physician familiarity and broader patient inclusion suggests the market still depends on education and evidence, not just demand. - North America’s lead and Asia-Pacific’s growth outlook suggest a mature market today and a faster-expanding opportunity abroad.

What's next: - The report expects continued gains from broader acceptance of inhaled insulin, stronger interest in rapid-acting alternatives and better patient compliance tied to convenience. - The company says future growth will also come from stronger focus on blood sugar control after meals and expanded use among wider patient groups. - The release directs readers to the report and company contact channels for more information.

The bottom line: - Afrezza’s market outlook is improving because diabetes is becoming more common and patients are showing more interest in easier, faster insulin options.